SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. on March 25, 2021. The report discloses the termination of a material definitive agreement regarding an equity offering program. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial metric disclosed relates to the equity offering program:
- Remaining Equity Capacity: Approximately $41.2 million of shares remained available for sale under the terminated agreement.
- Termination Penalties: $0 (The company is not subject to any termination penalties).
Material Changes
The primary material change is the termination of the Open Market Sale Agreement with Jefferies LLC, originally entered into on August 28, 2020. The agreement allowed for the sale of up to $45 million in common stock via an "at the market" offering. The termination notice was delivered on March 25, 2021, with an effective date of April 8, 2021.
Outlook, Risks, and Management Commentary
Management has elected to terminate the sales agreement without incurring penalties. The filing does not provide specific forward-looking guidance, risk factors, or commentary on future capital raising strategies beyond the termination of this specific program. The description of the original agreement is qualified by reference to the prior Form 8-K filed on August 28, 2020.
Key Facts for Investor Verification
- Verify the effective date of the termination (April 8, 2021) to confirm the cessation of the "at the market" offering.
- Confirm the remaining unsold equity capacity of approximately $41.2 million is no longer available under this specific agreement.
- Review the original Sales Agreement (Exhibit 1.1 to the August 28, 2020 Form 8-K) for full terms and conditions.
- Check for subsequent filings to determine if the company intends to replace this offering program with a new capital raising mechanism.